NLM Selects InTouch for Indexing in the MEDLARS System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

WASHINGTON-InTouch magazine, published by PRR for cancer patients and their family members, has been selected by the US National Library of Medicine (NLM) to be indexed and included in Index Medicus and MEDLINE.

WASHINGTON—InTouch magazine, published by PRR for cancer patients and their family members, has been selected by the US National Library of Medicine (NLM) to be indexed and included in Index Medicus and MEDLINE.

"It’s a real tribute to the editorial quality of InTouch," Steven T. Rosen, MD, said. Dr. Rosen, director of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, serves as medical editor-in-chief for InTouch, which just celebrated its third year of publication.

The National Library of Medicine looks to an advisory committee—the Literature Selection Technical Review Committee—to choose journals and other publications for citation. Composed of authorities knowledgeable in the field of biomedicine, the committee includes physicians, researchers, educators, editors, health science librarians, and historians who review and recommend titles for indexing.

The databases in the MEDLARS system in which InTouch will appear are Index Medicus and its online counterpart, MEDLINE, the system’s principal online bibliographic citation database. About 4,500 titles are indexed and included in the MEDLINE database, and 3,630 in Index Medicus.

"We’re delighted that the NLM has recognized the integrity and value of the information in InTouch," Dr. Rosen said. "Their endorsement furthers our mission, which is to give patients and their loved ones the most authoritative and up-to-date information on cancer prevention and treatment so that they can be better informed about their health care."

To search MEDLINE, go to PubMed located on the web at www.ncbi.nih.gov/entrez/query.fcgi.  

Related Videos
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Related Content